This Small-Cap Sudarshan Pharma Share Price Jumped 4 Percent. Here Is What This Stock Actually Does

The Sudarshan Pharma share price surged 4 percent on May 4, 2026, as the Sensex rallied on BJP winning West Bengal and crude easing from its $126 peak. The stock trades under Rs 50 with a market cap of Rs 689 crore. Before chasing the Sudarshan Pharma share price, investors need to understand the business, the sector tailwind, and the risks.

A pharma sector catalyst reinforced the move. The US government exempted Indian pharmaceutical exports from its reciprocal tariff framework in April 2026. India exports $8 billion of APIs and formulations to the US annually. The Sudarshan Pharma share price operates in this API and specialty chemicals space, making it a direct beneficiary of the tariff exemption.

Get free analyst research on pharma stocks on Univest.

Sudarshan Pharma Share Price: Key Data

The Business Behind the Sudarshan Pharma Share Price

Sudarshan Pharma Industries Ltd was incorporated in 2008 in Mumbai. It manufactures active pharmaceutical ingredients, specialty chemicals, intermediates, and generic formulations, and provides contract manufacturing services. Revenue has compounded at 27.95 percent annually over five years against the industry average of 10.04 percent. Net income has compounded at 65.64 percent versus the industry 20.02 percent. These numbers explain why the Sudarshan Pharma share price trades at 41x earnings.

The company developed its own API molecule, Vitamin B6, from raw chemistry through to finished product during FY26, and began Vitamin B1 development. This in-house capability strengthens the Sudarshan Pharma share price thesis as a vertically integrated pharma platform rather than a pure trading operation. A wholly owned subsidiary, Ratna Lifesciences, adds future pipeline potential.

Track the Sudarshan Pharma share price live with fundamentals on Univest.

The Margin Problem the Sudarshan Pharma Share Price Must Answer

Revenue growing 31 percent while PAT fell 29 percent year-on-year in Q2 FY26 is a clear warning. Operating margin fell from 10.15 percent in Q2 FY24 to 5.45 percent in Q2 FY26. At 41x P/E, the Sudarshan Pharma share price requires sustained earnings growth, not just revenue growth. Until margins recover, the gap between topline and bottomline performance remains the primary risk for the Sudarshan Pharma share price.

Debtor days have also risen from 92 to 116, indicating longer collection times. In February 2026, the GST department searched the registered office over five days. The company confirmed no violations were found, operations were unaffected, and the matter related to vendor non-compliance. These are manageable issues, but investors in the Sudarshan Pharma share price should monitor both metrics closely each quarter.

Screen Sudarshan Pharma fundamentals, margins and peer comparison on the Univest Screener.

Conclusion

The Sudarshan Pharma share price 4 percent jump on May 4 has two drivers: the broad Sensex rally on election results and the US pharma tariff exemption protecting Indian API exporters. The five-year growth record of the Sudarshan Pharma share price is genuine, with revenue CAGR of 27.95 percent. But margin compression from 10.15 percent to 5.45 percent and PAT declining 29 percent despite 31 percent revenue growth make the Sudarshan Pharma share price a stock to monitor carefully at 41x P/E, not chase blindly.

Disclaimer: Investment in the share market is subject to market risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data is sourced from NSE/BSE filings, company press releases, and publicly available reports. Verify all data before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Why did Sudarshan Pharma share price jump 4 percent today?

The Sudarshan Pharma share price rose 4 percent on May 4 due to the Sensex rally on BJP winning West Bengal and crude easing. The US tariff exemption on Indian pharma exports also lifted the entire API and formulations sector. Small-caps with thin liquidity tend to move sharply on broad market up sessions.

What is the Sudarshan Pharma share price 52-week range?

The Sudarshan Pharma share price has a 52-week high of Rs 53.50 and a 52-week low of Rs 21.62. It trades under Rs 50 with a market cap of Rs 689 crore. The stock is a small-cap in the pharmaceutical and specialty chemicals space on NSE and BSE.

What are the key risks in the Sudarshan Pharma share price?

Three key risks for the Sudarshan Pharma share price: operating margin compressed from 10.15 percent to 5.45 percent YoY, PAT fell 29 percent even as revenue grew 31 percent in Q2 FY26, and debtor days rose from 92 to 116. At 41x P/E, any further margin deterioration triggers a sharp correction.

What does Sudarshan Pharma Industries Ltd do?

The company behind the Sudarshan Pharma share price manufactures APIs, specialty chemicals, formulations, and generic medicines. It provides contract manufacturing and has developed in-house API molecules including Vitamin B6. Revenue has grown at 27.95 percent annually over five years, outpacing the industry average of 10.04 percent.

Recent Article

VRL Logistics Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Vraj Iron and Steel Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Voltas Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Voltamp Transformers Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Vodafone Idea Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook